// App-Quantinova.ai

243 : Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1–positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial.

Researchers

Presenter

  • Zev A. Wainberg

Principal Investigators

  • Eric Van Cutsem

  • Lucjan Wyrwicz

  • Keun Wook Lee

  • Iveta Kudaba

  • Marcelo Garrido

  • Hyun Cheol Cheol Chung

  • Jeeyun Lee

  • Hugo Raul Castro-Salguero

  • Wasat Mansoor

  • Maria Ignez Braghiroli

  • Nina Karaseva

  • Eray Goekkurt

  • Hironaga Satake

  • Joseph Chao

  • Uma Kher

  • Sukrut Shah

  • Pooja Bhagia

  • Josep Tabernero

Medical Centers

  • Keck School of Medicine of University of Southern California, Los Angeles, CA

  • National Cancer Center, EPOC, Chiba, Japan

  • University Hospitals Leuven and KU Leuven, Leuven, Belgium

  • Maria Sklodowska-Curie Memorial Cancer Center & Institute of Oncology, Warsaw, Poland

  • Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam,...

  • Latvian Oncology Center Rakus Gailezers, Riga, Latvia

  • P. Catholic University of Chile, Santiago, Chile.

  • Yonsei Cancer Center, Yonsei University College of Medicine, Seoul,...

  • Samsung Medical Center, Seoul, Korea

  • Angeles Medical Group, Guatemala City, Guatemala

  • The Christie Hospital, Manchester, United Kingdom

  • Institute of Cancer of São Paolo, University of São Paolo, São Paolo, Brazil

  • SPb SBHI Clinical Oncology Dispensary, St. Petersburg, Russian Federation

  • Hematology Oncology Practice Eppendorf, and University Cancer Center Hamburg, Hamburg, Germany

  • Kobe City Medical Center General Hospital, Kobe, Japan

  • City of Hope Comprehensive Cancer Center, Monrovia, CA

  • Merck & Co., Inc., Kenilworth, NJ

  • Vall d’Hebron University Hospital and Institute of Oncology (VHIO), UVic, IOB-Quiron, Barcelona, Spain

Locations

  • United States

  • Japan

  • Belgium

  • Poland

  • Republic of South Korea

  • Latvia

  • Chile

  • Guatemala

  • United Kingdom

  • Brazil

  • Russia

  • Germany

  • Spain

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastroesophageal junction (GEJ) adenocarcinoma

  • Solid malignancies

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Pembrolizumab

  • Capecitabine

  • Cisplatin

  • Adrucil injection

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • NCT02494583

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved